-24.8%
CCL vs MRNA
+511.3%
-536.1%
-30.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -2.2% | +2.4% | +0.2% |
| 7D | -5.0% | +5.5% | -10.5% | -5.2% |
| 30D | -20.3% | +158.7% | -179.1% | -23.7% |
| 3M | -15.1% | +182.1% | -197.3% | -21.4% |
| 6M | -15.1% | +151.8% | -166.9% | -20.3% |
| YTD | -21.8% | +393.6% | -415.3% | -36.2% |
| 1Y | -24.8% | +499.5% | -524.3% | -40.9% |
| All | -24.8% | +511.3% | -536.1% | -40.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling